Conclusions: Our study thus suggests that overexpression of EZH2, FAK and pFAK correlate with several well established pathologic risk factors and might predict a more aggressive biologic behavior in endometrial carcinoma making them potential therapeutic targets for treatment of endometrial cancer.
Head & Neck
with a soft palate tumor had nodal metastasis on presentation. One patient was lost to follow-up, and the remainder, were alive and without disease at time of last follow up (mean 38 months). All cases showed a uniformly univacuolar (signet ring) appearance embedded in a myxoid stroma and were mucicarmine positive. The IHC profi le is summarized in Table 1 . Three cases showed at least focal p63 staining, and 2 cases were positive for calponin and GCDFP-15. Interestingly, membranous E-cadherin was retained and mammaglobin was positive in all cases. All tumors were negative for ALK rearrangements. of HNSCC patients shows favorable responses to EGFR targeted therapy, correct selection of patient population who is destined to benefi t from EGFR targeted therapy is important to improve the effi cacy and effi ciency of EGFR-targeted therapy in HNSCC. Design: Total RNA samples were extracted from 8 cultured HNSCC cell lines and 1 immortalized normal keratinocyte cell lines, followed by real-time RNA analyses for the following genes involved in the EGFR signaling pathway: EGFR, E-cadherin, PTEN and SCOS1. Results: EGFR and PTEN genes are overexpressed in 7 out 8 (87%) HNSCC lines with an average increase of 5.8 and 2.5 folds respectively when compared to normal keratinocytes. E-Cadherin gene is down regulated in 6 out of 8 (75%) HNSCC lines with an average decrease by 61% when compared to normal keratinocytes. The average SOCS1 expression in HNSCC lines is slightly higher in 5 out of 8 (62%) an average increase of 1.2 folds when compared to normal keratinocytes. Conclusions: Overexpression of EGFR, PTEN and SOCS1 and downregulation of E-cadherin are common in HNSCC and a distinct EGFR signaling pathway gene expression pattern may be used to select for a subset of HNSCC responsive to EGFRtargeted therapies.
1285 Utility of Androgen Receptor, Her-2/Neu, Cytokeratin 5/6 and p63 Immunostaining in Distinguishing Salivary Duct Carcinoma from High Grade Mucoepidermoid Carcinoma RT Butler, S Byrd, ME Spector, JB McHugh. University of Michigan, Ann Arbor, MI. Background: Salivary duct carcinoma (SDC) can be misdiagnosed as high-grade mucoepidermoid carcinoma (MEC) (1). Distinguishing SDC from MEC is important as the former group of tumors is typically more clinically aggressive with poor 5-year survival rates. In addition, given high rates of androgen receptor (AR) positivity and Her-2/neu overexpression and amplifi cation in SDC, targeted therapies are indicated in some patients. No systematic studies looking at immunohistochemical markers to distinguish these two entities have been performed. Design: 48 cases of salivary duct carcinoma diagnosed at our institution were used to build a tissue microarray (TMA). This array, as well as a MEC TMA containing 81 carcinomas, including 9 high-grade tumors, were stained with antibodies to AR, Her-2/ neu, p63, CK 5/6 and k903 (34βE12). The results of immunostaining (except for Her-2/ neu) were scored with a modifi ed Allred score, utilizing intensity and percentage of tumor staining. Her-2/neu results were reported using an established scoring system. Sensitivity, specifi city, positive predictive value (PPV) and negative predictive values (NPV) were calculated. Results: Cytokeratin k903 was not helpful in distinguishing SDC from MEC as 84% and 98% were positive, respectively. AR and Her-2/neu positivity were specifi c for SDC (Table 1 ). In contrast, p63 and CK 5/6 were specifi c for MEC including the high grade MECs (Table 2) . Three MECs that were negative or had only focal staining were low grade cystic and mucous cell rich and would not be confused with SDC. SDC Conclusions: A panel of AR, Her-2/neu, p63 and CK 5/6 is helpful in distinguishing SDC from high grade MEC in cases where histologic overlap exists. This distinction is important as SDC is a highly aggressive malignancy with most patients dying of disease within 4 years of diagnosis. In addition, targeted therapies such as androgen deprivation and/or Herceptin may be indicated in SDC. 1. Chevevert, Jacinthe, Leon E. Barnes, and Simion J. Chiosea. Mucoepidermoid Carcinoma: A Five-Decade Journey. Virchows Arch. 2011; 458:133-140 .
1286 Salivary Duct Carcinoma -Altered Pathways for Targeted Therapy C Chattopadhyay, ME Kupferman, MS Kies, MD Williams. UT MD Anderson Cancer Center, Houston, TX. Background: Salivary duct carcinoma (SDC) is a high grade adenocarcinoma with median survival of less than three years. Identifying targetable pathways are needed for improved outcomes in this aggressive disease. Novel inhibitors of PI3K currently in clinical trials attempt to suppress misregulation which may be caused by loss of Phosphatase and tensin homolog (PTEN) expression, a tumor suppressor gene. Whereas direct inhibitors of c-MET, a proto-oncogene associated with motility, and proliferation, are also being studied which actives multiple pathways including that of PI3K. As little is known regarding these potential targetable pathways in salivary duct carcinoma, we sought to defi ne their incidence and correlate with clinical parameters. Design: A tissue microarray composed of formalin-fi xed paraffi n embedded tumor tissue from 62 salivary duct carcinomas formed the study cohort. Immunohistochemical analysis was performed for PTEN, c-MET and p-MET expression using standard techniques (PTEN 6H2.1, 1:100, Dako, Carpenteria, CA; c-MET, sc-10, 1:200, Santa Cruz). Each tumor was evaluated for expression in duplicate cores for: PTEN expression-negative or positive (cytoplasm and/or nuclear) and c-MET/ p-MET as 0 (no expression), 1+ (weak), 2+ (moderate) and 3+ (strong) staining. Results: Within the 62 SDCs, PTEN loss of expression was seen in 22 (34%), a similar incidence as seen in breast adenocarcinoma. C-MET showed high (2 or 3+) expression in 31(50%) of the SDCs and high p-MET expression was present in 27(43%) tumors. High-p-MET occurred in SDCs with all ranges of c-MET expression (0-3+).
No correlation was noted between clinical outcome and any of the markers analyzed.
Conclusions: Alterations in PTEN and MET expression occur in over a third of salivary duct carcinomas and may allow for targeted therapies through inhibition of the PI3K pathway and MET directly. Studies are on-going to delineate the molecular basis for these alterations. Background: An accurate diagnosis of laryngeal squamous cell carcinoma (LSCC) is essential for patient management. The diagnosis of LSCC, especially in superfi cial biopsies can present a diagnostic challenge for pathologists. The ability to diagnose LSCC would be greatly improved by the detection of a tumor-associated antigen. IMP3, an oncofetal protein plays an important role in embryogenesis and carcinogenesis of certain malignant neoplasms. The aim of this study was to investigate the expression of IMP3 in LSCC and to determine whether it can serve as a diagnostic biomarker for LSCC. Design: A total of 227 cases (laryngectomy, n=107; biopsy, n=120) of LSCC were obtained from the surgical pathology fi les of a tertiary Medical Center between 2000 and 2005. The diagnoses of all the cases were confi rmed by at least two pathologists.
Results: IMP3 showed strong cytoplasmic staining in 210 of 227 (93%) LSCCs. IMP3 positivity was detected in >50% of tumor cells in 156 (74%) cases, 26-50% of tumor cells in 18 (9%) cases and <25% of tumor cells in 36 (17%) cases. IMP3 expression was detected in 78 of 88 (89%) well-differentiated, 99 of 101 (98%) moderatelydifferentiated and 35 of 38 (92%) of poorly-differentiated LSCC. In contrast, the expression of IMP3 was undetectable in all adjacent benign squamous epithelium, including pseudoepitheliomatous hyperplasia. Conclusions: Our fi ndings indicate that IMP3 is a highly sensitive and specifi c positive biomarker for LSCC. IMP3 is highly expressed in LSCC but not in adjacent benign squamous epithelium, which suggests IMP3 may play an important role in the pathogenesis of LSCC as it has been shown to play a role in cell proliferation, invasion and migration.
Epigenetic Modulation of EGFR-Signaling Genes in HNSCC LN Clark, H Zhang, SA Schichman, C Fan. Univ Arkansas for Med Sciences, Little
Rock, AR; Central Arkansas Veterans Healthcare System, Little Rock, AR. Background: Epidermal Growth Factor Receptor (EGFR) signaling pathway appears critically important in the pathogenesis of head and neck squamous cell carcinomas (HNSCC). For the above reason, there has been immense interest in exploring targeted therapies aiming at EGFR, using either EGFR tyrosine kinase inhibitors (EGFR-TKI) or anti-EGFR monoclonal antibodies (EGFR-mab) for HNSCC. Characterization of epigenetic regulation of EGFR signaling genes (EGFR, E-Cadherin, PTEN and SCOS1) may lead to more effective treatment of HNSCC using EGFR-targeted therapies. Design: Promoter sequences of 4 EGFR signaling genes (EGFR, E-cadherin, PTEN and SCOS1) were analyzed for the presence or absence of CPG island using CpG Plot software. Total RNA samples were extracted, followed by real-time RNA analyses for these 4 genes from 8 cultured HNSCC cell lines, treated with or without a DNA demethylating agent, 5-aza-cytidine. Results: All 4 EGFR signaling genes (EGFR, E-cadherin, PTEN and SCOS1) contain a CpG island in their respective promoter sequence, ranging from 233 to 602 basepairs. Following treatment with a DNA methylation inhibitor, 5-azacytidine, increased expression of EGFR, E-cadherin, PTEN and SCOS1 genes was seen in 4/8 (50%), 4/8 (50%), 1/8 (12%) and 5/8 (62%) HNSCC lines respectively as compared to their original cells without 5-aza cytidine treatment.
Conclusions:
The presence of a CpG island in the promoter region and increased gene expression in response to DNA demethylation support that the expression of 3 EGFR signaling genes (EGFR, E-cadherin, SCOS1) may be suppressed by promoter hypermethylation and these genes can be unregulated by DNA demethylating agent in HNSCC. Therefore, DNA demethylating agent may be used to improve the response rate for HNSCC treated with EGFR-targeted agents (EGFR-TKI or (EGFR-mab). We investigated whether the common histopathologic and immunophenotypic features of SDC and Her2/Neu 3+ hormone receptor negative IDBC correspond to a similar miR "signature". 5 cases of SDC, 6 cases of IDBC Her/neu2 3+ and 4 cases of high grade ductal breast carcinoma in situ (DCIS) were selected from paraffi n embedded blocks from the OSU tissue archive. Representative areas of tumor were cored. RNA was isolated with Recover easy from Ambion and analyzed using Nanostring technology. The results were processed using SAM and cluster analysis module. To validate Nanostring results TaqMan Assays were used. The comparative C T method for relative quantitation of gene expression was used to determine miR expression levels. Results: The expression patterns of Her2/Neu 3+ IDBC and SDC were strikingly similar and much less so with high grade DCIS. We found that compared to SDC, Her/neu3+ IDBC had higher levels of miR142-3p and miR10a. When compared to SDC, DCIS had higher levels of miR10a also, together with miR99a, miR335 and miR331-3p and lower levels of miR19a and miR15a. All results were validated by Real Time PCR. Conclusions: A striking conclusion was that SDCs are closer to Her2/neu 3+ IDBC than the high grade DCIS. Only 2 miRs were differentially expressed compared to IDBC and 4 miRs differentially expressed compared to the high grade DCIS. One of the miRs differentially expressed -miR10a -was consistently higher in both high grade DCIS and Her2/Neu 3+ IDBC compared to the SDCs suggesting that this miR is breast specifi c and its expression is increased early in tumorigenesis. Expression of the other markers was heterogeneous, depending on the tumor sub type. C-ERBB2, c-KIT and Ki67 were associated with the tumor grade. Tumor grade and a high proliferation index (Ki67>20%) were associated with the progression free interval and survival. None of the other marker was. No mutation was found in EGFR/KRAS/ BRAF. 7% (7/104) of the tumors harbored a mutation at the codon 61 of HRAS. In epithelial and epithelial-myoépithélial carcinoma, the mutation rate reached 33%. Conclusions: Several tumor subtypes expressed frequently some targets of directed therapies suggesting potential therapy leads. For instance, high levels of C-ERBB2 and androgen receptors in salivary duct carcinomas or C-KIT over expression in myoepithetial carcinomas were found. The EGFR pathway seems intact suggesting a low effi cacy of small kinase inhibitors such as erlotinib or gefi tinib. The mutation of H-RAS, known to be important but not suffi cient to trigger urothelial carcinoma, calls for a broader screen to identify the pathways involved in malignant salivary gland tumors carcinogenesis. Conclusions: In our study, strong cytoplasmic and nuclear staining for p16 (3+) correlates with HPV PCR positivity. This pattern of p16 staining can be used as a surrogate marker for high risk HPV in lieu of HPV PCR. The presence of 1 to 2+ p16 staining in tumor and adjacent benign and dysplastic tissue is due to HPV independent mechanisms of p16 over expression since all of these cases were HPV PCR negative. HPV PCR positive study cases displayed varying amounts of keratinization typical of oral cavity location and not the basaloid growth pattern described in HPV positive tumors in prior studies, most of which were in an oropharyngeal location. This observation confi rms that a basaloid tumor growth pattern does not exclusively correlate with HPV positivity. Design: Three PES of HN were evaluated. The patients were ages 9, 43, and 71 years old, and tumor locations were posterior para-median neck, sinonasal, and retro-orbital respectively. Histologic and IHC sections were evaluated. Mutation analysis by direct sequencing of the promoter and 9 exons of SMARCB1, multiplex ligation-dependent probe amplifi cation (MLPA), and whole genome single nucleotide polymorphism (SNP) array were performed on frozen tissue from the two adult cases. Results: Morphologically the tumors were composed of poorly differentiated discohesive cells with eccentric, oval nuclei. Some tumor cells featured abundant eosinophilic inclusion-like cytoplasm, imparting a rhabdoid appearance. All tumors showed cytokeratin reactivity and lack of SMARCB1 expression; no myoid differentiation was identifi ed by IHC. There were no mutations in the promoter region or coding sequence of the SMARCB1 gene. One of the two tumors showed heterozygous deletion in chromosome 22 by MLPA and whole genome SNP array. Conclusions: Though rare, PES could occur in HN and should be differentiated from other HN tumors with epithelioid/epithelial differentiation by lack of SMARCB1 staining. Although positive cytokeratin and negative myoid markers favor PES over MRT, molecular analysis may further distinguish these closely related entities. The lack of mutations in the SMARCB1 gene has been reported in PES cases. Although deletion could be seen in both PES and MRT, the fi nding of heterologous deletion is more common in PES, but rare in MRT, which typically demonstrates homozygous deletions in SMARCB1. The lack of mutation and deletion in a HN PES warrants study to further investigate alternative mechanisms, such as epigenetic silencing, intronic mutations, RNA editing, or post transcriptional control, resulting in loss of SMARCB1 expression in PES. Squamous Cell Carcinoma H Gallai, RO Wein, K Kelsey, LW Solomon. Tufts University, Boston, MA; Tufts Medical Center, Boston, MA; Brown University, Providence, RI; Emory University, Atlanta, GA. Background: Amplifi cation and overexpression of the p63 gene on chromosome 3q27-29 is reported in 85% of head and neck squamous cell carcinomas (HNSCC). Overexpressed p63 functions as an oncogene. Protein overexpression can override host immune self-tolerance and produce a humoral immune response to self proteins. Previous studies detected serum p63 autoantibodies in 18% of patients with HNSCC. A case of HNSCC was serendipitously found to have p63 overexpression in the tumor cells by immunohistochemistry and serum autoantibodies to p63 by immunofl uorescence studies and enzyme-linked immunosorbent assay (ELISA) (titer >0.8 OD/controls <0.1 OD; OD = optical density 450nm). Our hypothesis is that some patients with HNSCC will have serum autoantibodies to p63 that are detectable by ELISA. Design: A case control study was designed to test serum from HNSCC patients for the presence of p63 autoantibodies. A validated ELISA was developed using recombinantly expressed p63 protein (N-terminal aa 1-205 of the ΔNp63 isoform) as the antibody capture agent. nQuery V7.0 software determined the sample size of 100 HNSCC cases and 100 age and sex matched controls (α = 0.05; power = 99%). Each serum was independently tested for IgG and IgA antibodies. Samples were tested in triplicate and the OD results averaged. SPSS for Windows V16 software was used for all statistical analyses. Receiver operator characteristic (ROC) curves were constructed to determine the optimal cut-off for classifying the disease state; the cut-off value that maximized the Youden Index was selected as the optimal cut-off. An independent-samples t-test was used and p-values less than 0.05 are considered statistically signifi cant. The sensitivity/ specifi city and positive/negative predictive values were calculated. Results: The ELISA test revealed a sensitivity of 54%, specifi city of 72%, positive predictive value of 67% and a negative predictive value of 61% for IgG antibodies. Testing for IgA antibodies had a sensitivity of 75%, specifi city of 47%, positive predictive value of 58.6% and a negative predictive value of 65%. Conclusions: Testing for p63 autoantibodies by ELISA is not specifi c or sensitive enough to be used for screening, prognosis, treatment response monitoring or detection of disease recurrence in HNSCC. Serum p63 autoantibodies are not a reliable biomaker for HNSCC.
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Spectrum of Problematic Metaplastic Changes in Salivary Gland
Tumors DR Gnepp, E Yakirevich, SK El-Mofty. Rhode Island Hospital, Providence, RI; Washington University, St. Louis, MO. Background: Metaplastic change is a common phenomenon in salivary gland neoplasms. Most of these tumors easily fi t into specifi c diagnostic categories. However, rare tumors present diagnostic challenges due to prominent metaplastic changes. In this study we analyzed the spectrum of salivary gland metaplastic changes causing diagnostic diffi culty over a 20-year period. Design: 56 salivary gland neoplasms with prominent metaplastic change were retrieved from pathology and consultation fi les . Ancillary studies (histochemistry, immunohistochemistry & EM) were applied as necessary. Results: Patients' age ranged from 17-87 (median 55) years with an equal male: female ratio. 45 cases originated from the parotid, 2 from submandibular and 9 from the minor salivary glands. Metaplastic changes were analyzed separately for epithelial, myoepithelial and stromal components. Epithelial metaplastic changes included, in descending order, squamous, oncocytic, mucoepidermoid, adenoid-cystic, and mucinous metaplasia. Myoepithelial cells demonstrated oncocytic, epithelial-myoepithelial, and adenoid-cystic like changes; the stromal component showed occasional lipomatous metaplasia. 36% showed more than one type of differentiation. Prominent squamous metaplasia was the most common metaplastic phenomenon and was most frequently associated with pleomorphic adenomas (PA) (14 of 26 cases) and Warthins tumor (9 cases); it was also seen in 2 oncocytomas. Diffuse oncocytic metaplasia was a characteristic feature of 20 tumors, including 8 PA, 5 acinic cell carcinomas, 2 mucoepidermoid carcinomas, 2 myoepitheliomas, 2 cystadenomas & 1 epithelialmyoepithelial carcinoma. Less frequent metaplastic changes included prominent mucoepidermoid (3), adenoid-cystic (3), mucinous (2), & epithelial-myoepithelial (1) differentiation. All the less frequent changes were seen exclusively in PA. Careful sampling and light microscopy looking for absence of destructive overgrowth of benign elements, lack of perineural, vascular, or extracapsular invasion & bland nuclear features will support a diagnosis of a benign metaplastic salivary gland tumor. Recognizing foci of residual classical appearing tumor in addition to the more prominent metaplastic component will allow proper classifi cation. Conclusions: Prominent metaplastic changes, although rare, may occasionally obscure the true nature of a salivary gland neoplasm. Recognizing the spectrum of metaplastic change will aid in establishing proper diagnoses and treatment. 
FGFR1 Amplifi cation in Metastatic Squamous
Design:
We put together a cohort of 227 patients suffering from HN-SCC, with 97 of these suffering from metastatic disease. Primary tumors and, where available, metastatic tumors were assessed for FGFR1 copy number status using fl uorescence in-situ hybridization (FISH). Results: 20,3% of primary HN-SCC displayed FGFR1 amplifi cations. Of interest, almost all metastatic tumor samples revealed a FGFR1 amplifi cation if the corresponding primary tumor harbored the amplifi cation. Conclusions: FGFR1 amplifi cation frequently occurs in primary and metastatic HN-SCC and proves as a potential target for small molecule therapy in non-operable or metastatic disease. Further functional studies and subsequent clinical trials are needed for further validation of our fi ndings.
SOX2 Amplifi cation Is a Common Event in Sinunasal Squamous
Cell and Undifferentiated Carcinomas F Goeke, A Franzen, R Mennon, S Huss, D Boehm, W Vogel, F Bootz, A Schroeck, S Perner. University Hospital Bonn, Bonn, Germany; University Hospital Cologne, Cologne, Germany. Background: Although carcinomas of the nasal cavities are known to differ signifi cantly from other cancers of the head and neck regarding causing noxa, clinical behavior and treatment, they share histological appearance. SOX2, a transcription factor-coding gene located at 3q26.33, is known to be recurrently amplifi ed in squamous cell carcinomas (SCCs) of the lung, esophagus, skin, penis, cervix uteri and oral cavity. The aim of our study was to assess if SOX2 amplifi cations also occur in different tumor entities of the paranasal sinuses. Design: Using fl ourescence in-situ hybridization, we assessed for SOX2 amplifi cation status in a cohort consisting of sinonasal SCCs (n=65), sinonasal undifferentiated carcinomas (SNUC, n=18), adenocarcinomas (n=25), and adenoid cystic carcinomas (n=18). Furthermore, we performed SOX2 immunohistochemical staining to quantify protein expression. Results: We detected SOX2 amplifi cations in 36% of sinonasal SCCs, 35% of SNUCs, 9% of adenocarcinomas, but none of the adenoid cystic carcinomas. Moreover, we found that the SOX2 amplifi cation is associated with a SOX2 protein overexpression in SCCs and SNUCs. Conclusions: SOX2 amplifi cation is not an organ site specifi c event, but is a frequent genetic alteration occuring in SCCs of various organs. Since SNUCs also harbor SOX2 amplifi cations in similar frequencies, we hypothesize that SNUCs may be undifferentiated SCCs.
Mammary Analogue Secretory Carcinoma: Expansion of a Clinicopathologic Profile and Identification of New Sources for
Recategorization CC Griffi th, S Chiosea, RR Seethala. UPMC, Pittsburgh, PA. Background: Mammary analogue secretory carcinoma (MASC) of salivary glands is a recently described tumor, histologically and biologically similar to secretory carcinoma of breast (ETV6-NRTK3 translocated). It is assumed that most were historically classifi ed as acinic cell carcinoma (AciCC) but other 'reservoirs' may exist. In order to expand and refi ne the clinicopathologic profi le of this rare tumor, we combine prospectively diagnosed MASC with a retrospective cohort derived from an array of diagnostic categories. Design: MASC were prospectively diagnosed over a 10 month period. Also, 297 archived salivary gland tumors, spanning several diagnostic categories, were reviewed by histomorphology and immunophenotype. Cases with pink vacuolated cytoplasm, luminal mucin, and/or strong S100 positivity were evaluated for ETV6 translocation by FISH (n=67). Clinicopathologic parameters on confi rmed cases were recorded. Results: A total of 36 MASC were confi rmed (9 prospective and 27 retrospective). Sources of retrospectively identifi ed MASC are summarized in the table. 30 cases were drawn from our consult fi les. Tumor sites were 26 parotid, 3 submandibular, 3 soft palate, 1 buccal mucosa, 1 upper lip and 1 base of tongue. MASC occurred in a wide age range (10-75 years, average 45.6) and had a male predominance (21 male:14 female). 15 tumors were uninodular/cystic, 13 infi ltrative and 4 multinodular/cystic. 18 tumors showed predominantly cribriform architecture, 9 solid, 5 intracystic and 4 papillary. 19 showed at least rare papillae and 22 at least some intracystic growth. Perineural and angiolymphatic invasion was common, 36.7% and 20% respectively. All tested cases were S100 positive (n=25) but half showed variable to focal staining. p63 showed peripheral staining in 5/22 cases, thus highlighting intraductal components. 5 cases were clinically aggressive -4 nodal metastasis and 1 disease related death following recurrence and metastasis. Conclusions: A wide array of diagnostic categories should be surveyed to more accurately characterize MASC, since in addition to AciCC, adenocarcinoma, NOS is a common source of MASC. MASC demonstrate a variety of morphologic features and range from low to high grade. Papillary and intracystic growth are fairly common. A subset of tumors behave aggressively.
Inverse Relationship between HPV-Infection and EGFR Gene Copy
Number in Head and Neck Squamous Cell Carcinomas S Hakim, S Moyano, E Bailon, A Valera, A Nadal, I Alobid, JJ Grau, L Alos. Hospital Clinic, Barcelona, Spain. Background: HPV-related squamous cell carcinomas of the head and neck are more prevalent in oropharynx and sinonasal tract. The better prognosis of these tumors when comparing with HPV-negative tumors has been repeteadly reported. The EGFR gene encodes a protein that can be activated by phosphorylation, inducing a signalling transduction cascade which ultimate in cell proliferation and survival. The EGFR overexpression has been linked to a bad prognosis in several cancers, including the head and neck carcinomas. Design: The aim of the study was to stablish the relationship between the HPV-infection and the EGFR gene status in a series of head and neck squamous cell carcinomas. Eighty eight patients with squamous cell carcinoma of the head and neck (50 sinonasal and 38 oropharyngeal) were included in the survey. HPV was detected by PCR using SPF10 primer set (Innogenetics Diagnostica, Barcelona, Spain). EGFR gene was studied by FISH using dual-colour EGFR Spectrum-red/CEP7 Spectrum-green probe (Dako, Carpinteria, CA, USA). Immunohistochemistry for P16
INK4 (Biocare Medical, Walnut Creek, CA, USA; Clone JC8; dilution 1:100) and EGFR (Dako; dilution 1:100) proteins was performed. Results: Tumors affected 69 males and 19 females with a median age of 62 (range 25-93) years. HPV16 was detected in 18 cases (20% of tumours). The HPV-positive carcinomas affected more frequently females (53% of patients) (p<0.0004), but no signifi cant differences in age were found. P16
INK4 positivity correlated with HPVdetection in 100% of cases. High EGFR gene copy number was detected in 85% of HPV-negative carcinomas (5 amplifi cations and 55 polysomies); and in 39% of HPVpositive carcinomas (7 EGFR polysomies) (p<0.0001). No EGFR amplifi cations were detected in HPV-positive carcinomas. No correlation between EGFR gene status and EGFR protein expression was observed. Conclusions: The molecular differences between HPV-positive and HPV-negative squamous cell carcinomas of the head and neck include the EGFR-gene status. This result may have great relevance to tailor oncological treatments in these patients. Background: Hashimoto's thyroiditis (HT) and the fi brosing variant of Hashimoto's thyroiditis (FVHT) are immune-mediated tumefactive lesions of the thyroid. IgG4-related disease (IgG4-RD) is now a widely recognized multi-organ system disease characterized by elevated serum and tissue concentrations of IgG4. The sine qua non of IgG4-RD is its histologic appearance: lymphoplasmacytic infl ammation, storiform fi brosis, and obliterative phlebitis. Recent data from Japan suggest that a subset of patients with HT also belong to the IgG4-RD spectrum. We address several questions pertaining to the relationship among HT and FVHT and the association of each of these diseases with IgG4-RD. Design: We evaluated 28 consecutive cases of HT and 9 cases of FVHT. The clinical, demographic, and serological data were recorded. The slides were stained immunohistochemically using antibodies to IgG4 and IgG, and the degrees of plasma cell infi ltration and IgG4 staining within samples were quantifi ed. For each case, the number of plasma cells staining for IgG4 and IgG was assessed in non-overlapping high-power fi elds. Results: Hypothyroidism was noted in 62% of HT and 85% of FVHT. Thyroid peroxidase antibodies were positive in all 10 cases of HT and all 4 cases of FVHT. FVHT demonstrated an exaggerated lobular pattern with lobules separated by storiform type fi brosis. This histological appearance was remarkably similar to the interlobular stroma of IgG4-associated sialadenitis and the type 1 variant of autoimmune pancreatitis. Follicular cells were predominantly arranged in a microfollicular pattern, and an intense infl ammatory infi ltrate composed of lymphocytes and plasma cells was identifi ed between follicles. The mean IgG4 counts per HPF in HT and FVHT were 4.9 and 27, respectively. The mean IgG4:IgG ratios in HT and FVHT were 19.0% and 61.4%, respectively. 
Conclusions:
The dense lymphoplasmacytic infi ltrate and interlobular fi brosis along with elevated numbers of IgG4 positive plasma cells link this disease to IgG4-RD. We propose that FVHT belongs to the IgG4-RD spectrum.
WNT-ß-Catenin Is Upregulated in Very Aggressive Tumor Pattern of Invasion
The WNT pathway is a critical to proliferation, differentiation, oncogenesis and is upregulated in many cancers. Among the downstream effects, WNT-β-catenin is involved in tumor invasion. We developed 4 cell lines from oral/ oropharyngeal SCC, which are unique as they are matched to different worst patterns of invasion (WPOI) in the corresponding resections. These histopathological WPOI were developed and validated by us as outcome prognosticators. Design: Cell lines were derived from fresh resections, cancer cells were sorted from cancer-associated fi broblasts by fl ow cytometry and grown in keratinocyte media/ keratinocyte growth supplements. HPV was determined by RT-PCR with HPV16/18 E6/E7 primers, with appropriate controls. Invasion was measured with the BioCoat Matrigel chamber, 24h after stimulation with TGFß. Cells that invaded across the chamber membrane were counted after fi xation and staining. UAB-1, UAB-4, and the corresponding frozen samples from the 2 resections were assessed for WNT signalling with the RT2 96 well RT-PCR kit (SABiosciences). Results: Table 1 shows the clinicopathologic features for these cells. RT-PCR results shows up-regulation of WNT-pathway in tumor-2/UAB-4, compared to tumor-1/UAB-1. Background: EBV, an orally transmitted herpesvirus that targets B cells and epithelial cells, is associated with development of both B cell lymphomas and nasopharyngeal carcinoma. Infection of B cells is initiated by binding of virus to the complement receptor CD21. Infection of CD21-negative epithelial cells is ineffi cient but effi cient infection can be achieved if expression of CD21 is engineered. Whether EBV infection plays an etiologic role in oral squamous cell dysplasia (OSD) and malignant transformation is unclear. The aim of this study was to evaluate CD21 expression in OSD and its association with the epithelial stem cell marker CK19 that is elevated in oral squamous cell carcinoma (OSCC). Design: Formalin-fi xed paraffi n-embedded tissue blocks were retrieved and separated by pathologic grade as follows: normal margin epithelium of OSD (n=6), low-grade OSD (LSD, n=8) and high-grade OSD (HSD, n=21). Squamous cells were isolated by laser capture microdissection. Isolated mRNA was amplifi ed using qRT-PCR with target primers specifi c for the CD21 exons coding for the EBV binding site, for CK19 and for EBV small RNA, EBER1. CK19 expression was also examined by immunohistochemistry (IHC). IHC for CD21 has not proven reliable. Results: Normal margins of OSD were negative for both CD21 and EBV. CD21 expression was found in 12.5% (1/8) LSD samples and 57.1% (12/21) HSD samples. Transcript levels were 0.35 and 2.97 fold higher, respectively, than in the Akata B cell line (set arbitrarily at 1). EBV could also be detected in some samples of OSD. CK19 was detected in normal epithelial margin at low transcript levels. Transcript levels were increased signifi cantly in EBV positive OSD (P<0.025), but not in EBV negative OSD (p>0.05). Increased CK19 was confi rmed at the protein level by IHC. Conclusions: CD21 mRNA is expressed in dysplastic oral epithelium, and is upregulated as the grade of dysplasia increases. Expression of CK19 is increased in premalignant dysplasia and the increase is correlated with the presence of EBV. CK19 is a stem cell marker which is elevated in OSCC and is associated with increased epithelial mesenchymal transition. Increased susceptibility of epithelial cells to EBV may be involved in the process of oral squamous cell differentiation and precipitate malignant transformation. INK4A and cyclin D1 expression in a variety of benign and malignant salivary gland tumors, and to investigate p16 expression as a surrogate marker for HPV infection in MEC. Design: 44 cases were selected from the Pathology fi les in our hospital centers. The series includes 31 malignant tumors (14 MEC, 5 acinic cell carcinomas (ACC), 5 polymorphous low grade adenocarcinomas (PLGA), 6 (AdCC) and 14 benign tumors (4 benign cysts, 5 Warthin tumors and 5 pleomorphic adenomas (PA). All cases were tested by IHC for p16 INK4A and Cyclin D1. Testing for HPV wide spectrum (HPV-WS) was performed by in situ hybridization in all MEC cases. Staining intensity was recorded semi quantitatively (on a scale from 0 to 4+). Fisher's exact test and correlation with a p <0.05 were used to assess the differences and correlation in frequencies of various parameters tested. Results: Cyclin D1 and p16 are expressed similarly in malignant and benign tumors (p=0.126 and p =0.464, respectively).None of the MEC cases showed nuclear reactivity for HPV-WS. Statistical analysis showed positive correlation between Cyclin D1 and p16 expression. Conclusions: 1) CyclinD1 and p16
INK4A are overexpressed in both malignant and benign salivary gland tumors but not within the normal salivary gland epithelium; the lack of statistical difference between the two groups suggests that these deregulations are unrelated to their biological behavior; 2) The absence of nuclear reactivity for HPV-WS in all MEC cases suggests that p16 overexpression in these tumors cannot be used as a surrogate marker for viral infection; 3) The positive correlation between CCND1 and p16
INK4A suggests that CyclinD1 gene over expression may represent a priamry tumorigenic event in salivary gland neoplasms leading to secondary p16
INK4A over expression by an ineffective positive feedback mechanism, similar to that seen in HPV infection. Further molecular studies targeting the CyclinD1 gene locus are warranted.
Prognostic Features and Grading in Mucoepidermoid Carcinoma of Major Salivary Glands
N Katabi, R Ghossein, S Ali, S Dogan, D Klimstra, I Ganly. MSKCC, New York. Background: Mucoepidermoid carcinoma (MEC) has widely diverse biologic behavior. Grading MEC is important prognostically and therapeutically; however, there is no uniformly accepted grading system. The aim of this study is to assess adverse prognostic features of MEC in relation to outcome and to compare different grading systems. Design: 72 cases of MEC were subjected to a detailed histopathologic analysis. Four grading systems were used: AFIP, Brandwein, Healy, and our own (personal system mainly based on the architecture and cytology of the tumor). 5 yr estimates of survival were performed. Results: 20 of 72 cases were misdiagnosed as MEC; 4 as low grade (LG) and 18 as high grade (HG). The 18 HG were reclassifi ed as follows: 2 salivary duct carcinoma, 11 squamous cell carcinoma, and 3 HG carcinoma unclassifi able. Among the 52 MEC, median patient age was 50 with female predilection of 1:2. Tumors were predominantly located in the parotid (50 parotid/2 submandibular). Mean tumor size was 1.77 cm. Lymphoid stroma was found in 83% of tumors. Perineural invasion, vascular invasion, and lymph node metastasis were identifi ed in 19%, 6%, and 9%, respectively. Only 1 patient developed distant metastasis to the lung. Median follow-up was 50 months (1-237). 5 yr estimates of disease specifi c survival (DSS) and recurrence free survival (RFS) were 95% and 89%, respectively. Mitosis (≥4/10 HPFs), necrosis, pleomorphism, focal keratinization, desmoplasia, and lymph node metastasis were associated with adverse DSS and RFS (P < .002). Vascular invasion, tumor size > 2cm, and infi ltrative borders were associated with adverse RFS (P < .002). In all 4 grading systems, LG and intermediate grade (IG) had similar DSS and RFS survival but much better outcome than HG (P<0.007). All patients with a low mitotic rate and no necrosis did not recur except for 1 patient with a positive margin. All patients with tumors showing a high mitotic rate and necrosis died or recurred. Lack of consensus among grading systems was found in 23 out of 52 cases. Among the 23 cases, 3 LG tumors and 1 IG using AFIP criteria were upgraded to HG using Brandwein. None of these 4 patients died or recurred. Conclusions: 1) HG MEC is very rare and the majority of previously diagnosed HG MEC cases are misclassifi ed. 2) There is no difference in outcome between LG and IG using any grading system. 3) Consideration should be given to stratify MEC into two grade categories based on relatively objective criteria such as mitosis sand necrosis. Background: The signifi cance of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (SqCC) is well established. However, HPV oncogenesis in the larynx is less clear. p16 expression is strongly associated with HPV in oropharyngeal SqCC and its utility as a surrogate marker has been validated. Implications of laryngeal SqCC p16 expression are less well described. Recently, a specifi c HPV test has been developed; chromogenic in situ hybridization (ISH) to detect mRNA of the E6/ E7 oncogenes, which are directly involved in dysregulating the cell cycle in HPV oncogenesis. Herein, we examined laryngeal SqCC using p16 immunohistochemistry (IHC), chromogenic ISH for HPV-16, high risk (HR) HPV DNA and E6/E7 mRNA HPV H7 RNA scope. Design: A computerized search yielded 101 SqCC of the larynx at OSUMC, which were classifi ed as supraglottic, glottic, or subglottic. Tumor sections were used to construct tissue microarrays (TMA). The TMAs were stained for p16 using routine IHC methods and evaluated for intensity (0-3+) and percent of tumor cells stained. Staining of <5% was considered negative. The TMAs were also stained using ISH for HPV-16 and HR-HPV DNA as well as E6/ E7 mRNA H7 (16, 18, 31, 33, 35, 52, 58) , which were interpreted as positive or negative. Results: p16 expression was present in 20/101 (18%) laryngeal SqCC. Supraglottic SqCC showed rate of 30% (14/46) including 8 with strong and diffuse staining (3+, >75%). Glottic SqCCs had a positive rate of 8% (4/52) with weaker staining. 1/9 (11%) subglottic SqCC was positive with only focal staining. The difference in p16 expression for supraglottic, glottic and subglottic groups were statistically signifi cant (p<0.05). All tumors were negative for HPV-16 and HR-HPV ISH. HPV E6/E7 mRNA H7 was detected in 5% (1/20) of p16 positive tumors. This tumor was supraglottic with strong and diffuse p16 expression.
Conclusions:
Our study indicates a low overall frequency rate of 18% p16 positivity in SqCC of the larynx with predilection for supraglottic sites. Only 5% of p16 positive cases harbour HPV using a highly sensitive assay. Our data seems to suggest that p16 expression does not correlate with HPV infection in the larynx and might be unrelated to HPV oncogenesis. Background: In the United States and Europe, about 40-80% of head and neck squamous cell carcinoma are caused by human papillomavirus (HPV). p16 expression and HPV infection have been demonstrated to be a favorable biomarker for patients with head and neck squamous cell carcinoma. However, p16 expression and its prognostic value of laryngeal squamous cell carcinoma in patients from China are unknown. We aimed to investigate p16 expression and its prognostic value in Chinese patients with laryngeal squamous cell carcinoma. Design: A total of 236 patients with laryngeal squamous cell carcinomas (laryngectomy, n=111; biopsy, n=127) obtained from the Surgical Pathology fi le (2000) (2001) (2002) (2003) (2004) (2005) , Cancer Center of SunYat-sen University, Guangzhou, People's Republic of China were examined by immunohistochemistry for p16 expression. Overall survival was measured from the date of laryngectomy or biopsy to the date of death, and was censored from the date of last follow-up. Median follow-up period was 5 years and 3 months (63 months, range 7-123 months). Results: immunostaining is extensively used as a surrogate marker for transcriptionally-active HPV. While diffuse staining is generally accepted as being positive, the signifi cance of partial staining has not been established, nor has the cutoff for extent of p16 staining that should be used to identify a tumor as HPV-related or unrelated. Design: From 3 other large studies (>400 cases) utilizing p16 immunohistochemistry, we identifi ed all cases with partial positive staining. The p16 stained slides were reviewed by 3 study pathologists for staining (both nuclear and cytoplasmic) extent (in quartiles) and also for % of staining that was confl uent (i.e. back to back positive cell staining). Tumors were histologically typed (keratinizing, nonkeratinizing, or nonkeratinizing with maturation) and tested for high risk HPV by RNA in situ hybridization (ISH) and reverse transcriptase PCR. Results: For the 16 cases, there were 2 4+ (13%), 5 3+ (31%), 6 2+ (38%), and 3 1+ (19%) p16 staining tumors. Extent of staining ranged from 5 to 90% of cells positive with 25% or more confl uent staining in 4/16 (25%). Table 1 shows histology, HPV testing, and p16 results by quartile. Background: Grading of squamous dysplasia on head-neck mucosal biopsies plays a central role in management, but is subjective. None of the limited studies on observer variation in grading has included community pathologists. This study compares observer variation in grading between subspecialized head-neck pathologists (HNP) and general surgical pathologists (GSP). This is the fi rst study employing digital imaging as a media for such evaluation at this site. Design: Aperio scanned images of a random selection of 50 head-neck mucosal biopsies were circulated to 7 HNP (4 surgical and 3 oral) and 7 GSP (3 academic and 4 community). Participants were asked to assign 3-tier (negative, mild, moderate, severe) and 2-tier (negative, low, high) grades on each case. Results were analyzed for observer agreement using Krippendorf alpha (KA), a measure more appropriate than kappa statistics for ordinal data. 5 cases rated suboptimal were excluded. Design: 48 cases of PSCC were retrieved from our surgical pathology database and were reviewed by 3 study pathologists, following morphologic criteria as defi ned by the WHO. An RNA insitu hybridization (ISH) assay to detect high-risk HPV E6/E7 mRNA was used as were DNA ISH for high-risk HPV and immunohistochemistry (IHC) for p16 and p53. Clinical follow-up data were obtained by chart review. Results: 7 cases were in the oral cavity (OC), 19 in the oropharynx (OP) and 22 in the larynx. Two morphologic types of PSCC were identifi ed: a keratinizing type (K) in which the epithelial cells showed a maturation trend with minimal surface parakeratin, and a nonkeratinizing type (NK) in which the papillae were completely covered by immature basaloid cells. Transcriptionally active HPV was documented in a number of tumors; The majority of these were found in younger patients and occured more commonly in the OP. They showed NK morphology, were p16 positive and p53 negative. Background: Sox10 is known as a transcription factor crucial for specifi cation and maturation of the neural crest, and maintenance of Schwann cells and melanocytes. In a murine model, Sox10 is also shown to be highly expressed in myoepithelial and acinic cells at the salivary glands. However, there are few reports that studied Sox10 expression in human salivary glands and tumors. Design: We collected formalin-fi xed paraffi n-embedded specimens of 15 unremarkable salivary gland tissues (12 parotid glands and 3 submandibular glands) and 15 tumor tissues resected surgically between 1998 and 2010. These tumors comprised of 5 acinic cell carcinomas (AciCC), 3 adenoid cystic carcinoma (ACC), and one case each of epithelialmyoepithelial carcinoma (EMC), salivary duct carcinoma (SDC), mucoepidermoid carcinoma (MEC), carcinoma ex pleomorphic adenoma (Ca-Ex-PA), carcinoma not otherwise specifi ed (CaNOS), pleomorphic adenoma (PA), myoepithelioma (ME). The expression of Sox10, p63 and SMA were immunohistochemically examined and correlated with all types of these salivary glands and tumors. Results: In all 15 unremarkable salivary glands, Sox10 was expressed in the nuclei of most (>80%) of the myoepithelial cells and luminal (epithelial) cells in acini and intercalated ducts, but not expressed in basal cells and luminal cells of striated and excretory ducts. p63 was confi rmed to be expressed in myoepithelial and basal cells but not in all luminal cells, and SMA was confi rmed to be expressed only in myoepithelial cells. And Sox10 was expressed luminal and myoepithelial cells of all cases of AciCC, ACC, EMC, and PA, but was completely negative in the cases of SDC, MEC, and CaNOS. In a ME, Sox10 was expressed in myoepithelial cells. Conclusions: Sox10 was expressed in most of the luminal and abluminal cells of acini and intercalated ducts in all human salivary glands examined. In the salivary tumors, Sox10 was positive in tumors that have similarity to acinus or intercalated duct, i.e. AciCCs, ACCs, EMC, and ME, but negative in those that have similarity to striated and excretory duct, i.e., SDC and MEC. Sox10 can be one of useful markers for the identifi cation of cellular genealogy and diagnosis of salivary gland tumors. The diagnosis of squamous dysplasia in head and neck (H&N) biopsies is subjective and no markers exist to reliably identify a clonal squamous proliferation. CT antigens comprise a group of proteins that are normally only expressed in germ cells but can be aberrantly activated in cancers, making them potential diagnostic markers. Similarly, p53 gene mutation and protein overexpression is a crucial and clonal event in carcinogenesis. In this study, we evaluated the frequency of CT and p53 expression in H&N squamous cell carcinoma (SqCC) and sought their potential as diagnostic markers in biopsy specimens. Design: Protein expression of 8 CT antigens (MAGEA, GAGE, SAGE1, NY-ESO-1, CT7, CT10, CT45 and NXF2) and p53 was immunohistochemically evaluated in a tissue microarray of 76 H&N SqCC. 118 biopsy specimens with variable degrees of squamous dysplasia, obtained from 87 cases, were examined on whole sections for 6 CT antigens (MAGEA, GAGE, NY-ESO-1, CT7, CT10, and CT45, in an antibody cocktail) and p53. Unequivocal CT antigen staining in any tumor cell and nuclear p53 staining in >20% of tumor cells were interpreted as positive. Results: Fifty of 76 invasive SqCC (66%) expressed at least one CT antigen. Overexpression of p53 was found in 27 of 76 cases (36%). Sixty-two SqCC (82%) expressed CT antigen and/or p53. Among the 118 biopsy specimens, 9 were CT positive, 4 were p53 positive, and none was double positive. Of the papillary lesions, 1 (with moderate dysplasia) of 55 was focally CT positive and none were p53 positive. In contrast, of the 65 fl at lesions, 8 were CT positive and 4 were p53 positive. These 12 specimens ranged from mild dysplasia to carcinoma in situ histologically and were from 10 patients, 6 of which had a prior or concurrent diagnosis of SqCC. (Figure: moderate dysplasia in a patient with prior SqCC, positive for CT expression).
p16 Expression and Prognostic Value in Laryngeal Squamous
HPV-31 Is the Most Common HPV Subtype Isolated from Oropharyngeal Squamous Cell Carcinomas in South Africa
Conclusions:
More than 80% of invasive H&N SqCC showed CT antigen expression and/or p53 overexpression. Although lack of CT/p53 expression is not diagnostically useful, positive CT or p53 immunostains may serve as a specifi c marker for malignant transformation, distinguishing these lesions from squamous lesions with benign atypia. Background: Non-intestinal type sinonasal adenocarcinomas (non-ITAC) and intestinal type adenocarcinomas (ITAC) are rare biologically distinct sinonasal tumors that can be immunophenotypically distinguished using markers like CK7, CK20, and CDX2. We had surprisingly noted one case of sinonasal seromucinous hamartoma (SSH), a potential precursor to non-ITAC, which showed focal CDX2 immunoreactivity in association with squamoid morules. To survey this potential diagnostic pitfall, we evaluated the morphologic and immunohistochemical characteristics of a series of SSH, non-ITAC, and ITAC. Design: Three SSH, fi fteen (9 low grade (LG), 6 high grade (HG)) non-ITAC (5 papillary, 3 lobular, 2 cystic, 4 solid and 1 cribriform), and sixteen ITAC (4 papillary, 5 colonic, 1 solid, 6 mucinous) were retrieved from our fi les. One case of SSH arising in left middle turbinate was associated with a non-ITAC of the right sinonasal cavity. Histologic features, including growth pattern, metaplastic changes, and immunohistochemical profi le were tabulated. Results: All SSH (3/3) were CK7 positive, S100 positive, and CK20 negative. One SSH with morular metaplasia showed CDX2 positivity restricted to morules. All ITACs tested were CK20 positive (10/10), CDX2 positive (6/6), and 9/10 were CK7 positive. Squamous or morular metaplasias were not seen in ITAC. All non-ITACs tested were CK7 positive and CK20 negative (9/9). A subset of LG non-ITACs (3/5) were S100 positive, similar to SSH, and DOG1 (an acinar selective marker) positive. Three cases showed squamoid features accompanied by focal p63 and CK 5/6 reactivity. One non-ITAC with metaplasia showed morules with CDX2 and nuclear beta-catenin positivity. The other cases with squamous metaplasia were CDX2 negative. Conclusions: SSH and non-ITAC add to the list of glandular lesions that may show morular metaplasia. Similar to other tumors, the morules are characterized by nuclear beta catenin and CDX2 reactivity which is a potential diagnostic pitfall in the sinonasal tract. However, the restriction to morules and lack of CK20 reactivity distinguish SSH/non-ITAC with morular metaplasia from ITAC. The shared morphology and immunophenotype between SSH and a subset of non-ITAC supports an etiologic relationship between these entities. In addition, we compared p16 expression with HPV status in these tumors. Design: We studied 84 MEC with known HPV status. E6 protein was determined by mouse monoclonal HPV16/18 E6 (C1P5) primary antibody and goat anti-mouse secondary antibody conjugated to Alexa 488. Immunohistochemistry stains were performed for p16, and expression was categorized for staining intensity (scale 0-4) and percent staining distribution, for the nuclei and cytoplasm of the squamous and mucinous tumor elements. All slides were examined blinded to HPV status by two pathologists.
Results: E6 protein was demonstrated in 18/84 MEC (21%), with either nuclear and/ or cytoplasmic staining in both mucinous and squamoid tumor elements, as shown in fi gure 1 (arrows). Background: Chronic sialadenitis is a relatively common disease in which microliths play an important role in its pathogenesis. The suggestion that all cases of chronic sclerosing sialadenitis are IgG4-related sialadenitis is not supported by evidence, and we have recently reported a case with the histological features of chronic sclerosing sialadenitis that lacked signifi cant numbers of IgG4 plasma cells (Histopathology 2011 (Histopathology , 58: 1164 . Design: We have undertaken an investigation of an archive of 105 cases of chronic submandibular sialadenitis that had been previously extensively characterized (Histopathology 1997, 31:237-51) . The degree of fi brosis, periductal lymphoplasmacytic infi ltrate, and the presence or absence of liths, granulocytic epithelial lesions (GEL) and phlebitis were assessed. The number of IgG4 plasma cells was counted in 10 HPFs and samples were classifi ed as "0": no IgG4 plasma cells, "1": scattered IgG4 cells and; "2": > 50 IgG4 cells per HPF. The ratio IgG4:IgG was also investigated.
Results:
The degrees of infl ammation, atrophy and fi brosis varied greatly, and 67 cases were classifi ed as chronic sclerosing sialadenitis. Sialoliths were present in 63 out of 89 cases in which the presence or absence of sialolithiasis could be confi rmed. The number of IgG4 plasma cells was "0" in 89 cases, "1" in 19 cases, and "2" in three cases, in which there was sialolithiasis. There were relatively more widespread atrophy, fi brosis and infl ammation and more sialoliths in glands with IgG4 cells described as 1 than in glands with 0. There was widespread atrophy, fi brosis and infl ammation in the 3 glands with IgG4 cells above 50 per HPF, which surrounded the ducts that contained sialoliths.
Conclusions:
The incidence of IgG4-related sialadenitis is unknown with about 52 cases reported in the literature. However, our investigation adds further evidence that IgG4-related sialadenitis is rare. In addition, our fi ndings raise the possibility that IgG4 plasma cells represent a local reaction to sialolithiasis rather than a systemic process in the three cases with signifi cant numbers of IgG4 plasma cells. Background: Head and neck squamous cell carcinoma (HNSCC) treatment had undergone important changes, in particular due to the organ preservation and the advent of chemotherapy. The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and has been associated with resistance to platinum-based chemotherapy. The purpose of this study was to evaluate the role of ERCC1expression with p16 and Ki-67 as predictive markers in the response to platinum-based induction chemotherapy in patients with HNSCC. Design: 208 patients treated from 2000 to 2006 by an induction chemotherapy regimen for HNSCC were included retrospectively. ERCC1 (8F1 and FL297 clone), p16 and Ki-67 staining were performed on paraffi n-embedded tumor tissue collected before chemotherapy. We assessed response to treatment, progression-free survival (PFS) and overall survival (OS). Results: Respectively, 68% (142/208 patients) and 81.5% (163/200 patients) of HNSCC showed low expression of 8F1 and FL297 ERCC1. No correlation was found between the two clones (p=0.1). There was no correlation between the expression of 8F1 ERCC1, FL297 ERCC1 and Ki-67 and the response to induction chemotherapy, OS or PFS. However, in the subgroup of 129 patients treated with induction cisplatin-5FU chemotherapy, a low expression of 8F1 ERCC1 was signifi cantly associated with a better response (p=0.027). Over expression of p16, found in 34.5% of cancers of the oropharynx was signifi cantly correlated with a better OS (p=0.0007) and a better PFS (p = 0.01).
ERCC1, P16 and Ki-67 Immunohistochemichal Expression as Predictive and Prognostic Marker in Head and
Conclusions:
These results suggest that ERCC1 expression might be a useful predictive marker of HNSCC in patients treated by cisplatin-based chemotherapy. The 8F1 ERCC1 clone appears to be the best for immunohistochemical analysis; clone FL297 did not show any association with treatment response and survival. Independently, our study confi rms the prognostic value of the over expression of p16 in carcinoma of the oropharynx. ), but in multivariate it did not by either method (p>0.1 for each). In just the HPV RNA ISH positive patients, negative cyclin D1 also did not correlate signifi cantly with overall survival (visual p=0.58; digital p=0.067). Conclusions: Cyclin D1 expression (as < versus > 30%) correlates strongly with patient outcomes in OSCC. However, this correlation appears to be due to high correlation with HPV status and other prognostic variables so that cyclin D1 does not predict prognosis among just the HPV/p16 positive population.
observed lack of recurrence of sinonasal LCHs (2). As our experience and case reports have observed diffi culty in extirpation of these lesions, we performed a clinicopathologic institutional review of sinonasal LCH. Design: With IRB approval, we performed a systematic search of our institution's case fi les and medical record system, reviewing and tabulating clinicopathologic, histologic, and follow-up parameters of nasal or sinus lesions diagnosed as LCH or PG between 1989 and 2009. Lesions meeting Mills et al. criteria were included. Statistical analyses included two sample tests, chi-square tests, and Kaplan-Meier Analysis. Results: Of cases identifi ed, 34 of 45 (76%) met criteria for LCH. Presenting symptoms included epistaxis (78%), obstruction (34%), and pain (3%). No sex predilection was observed (17/18; M/F), nor was any difference in distribution of ages by sex (p=0.97) or of sex by age group (pediatric, reproductive age, and >40 years, p=0.48), with a median age of 39 years. Pregnancy was associated with 5/34 (15%) cases, while antecedent trauma was reported in 4/34 (12%). Histologically, ulceration was identifi ed in 23 of 34 (68%) and prominent mitotic activity (>10/10 HPF) in 3 of 34 (9%). Cellularity of lobules was low in 8/34, moderate in 22/34, and dense in 4/34. In terms of recurrence free survival over a median follow-up of 36 months, we observed recurrence after excision in 13 of 34 cases (38%), including cases of clinically treated, unbiopsied recurrence (7/34, 21%) and biopsy-documented recurrence (6/34, 18%). Conclusions: Review of a contemporary series of LCH observed similar distributions of age and sex, presenting symptomatology, and association with pregnancy to prior studies. In contrast to the only recent series (2), recurrence in this cohort was more frequent, comparable to that originally reported. Our fi ndings suggest sinonasal LCH demonstrates greater local tenacity than previously appreciated. Awareness of this may aid in avoiding misdiagnosis of these lesions as other vascular lesions such as angiofi broma and angiosarcoma. E-JM Speel, EVE Bergshoeff, TJH Siebers, SAJHM Fleskens, A Haesevoets, JAWM van der Laak, TMAW Merkx, RP Takes, PJ Slootweg, JJ Manni, B Kremer . Maastricht University Medical Center, Maastricht, Netherlands; Atrium Medical Center, Heerlen, Netherlands Antilles; St Radboud University Medical Center, Nijmegen, Netherlands. Background: A major dilemma in the management of patients with precursor lesions of the head and neck mucosa lies in deciding which lesions will progress into carcinoma. Currently used treatments are guided by histopathological examination, which however is troubled by inter-observer variability. The aim of this study was to evaluate the value of chromosomal instability (CIN) detected by fl uorescence in situ hybridization (FISH) for the identifi cation of head and neck premalignant lesions at risk for progression. Design: We examined a series of premalignant oral mucosa lesions (n=106 patients) and laryngeal precursor lesions (n=75 patients) by means of FISH on paraffi n-embedded tissue sections using chromosome 1 and 7-specifi c centromere probes. Cell nuclei were analyzed for CIN in the fl uorescence microscope, indicated by the presence of chromosome imbalances and/or polyploidization. Results were correlated with histopathological data as well as with collected clinical follow-up data. Results: In both oral and laryngeal precursor lesions, the 5-year progression-free survival rate was ∼90%. Outcome of routine histopathology did only predict malignant progression when comparing severe dysplasia with lower stage precursor lesions (hyperplasia, mild en moderate dysplasia) (p≤0.038). CIN was detected in all different subgroups of histopathological differentiation. Moreover, the percentage of precursor lesions harboring CIN increased with progressing histopathological stage. CIN was signifi cantly associated with a lower progression-free survival as compared with lesions without CIN (p<0.001).
Chromosomal Instability Predicts the Progression of Premalignant Head and Neck Lesions
Conclusions:
The tumorigenesis of the head and neck mucosa is associated with the development of CIN, which can reliably identify lesions at risk for malignant progression. Therefore, intensive follow-up and/or a more aggressive treatment of lesions with CIN should be considered, and for example examined in prospective studies.
Analysis of HPV Integration Sites in Oropharyngeal Squamous
Cell Carcinomas E-JM Speel, CU Huebbers, NC Olthof, J Kolligs, SF Preuss, U Drebber, B Kremer, JP Klussmann. Maastricht University Medical Center, Maastricht, Netherlands; University of Cologne, Cologne, Germany; University Hospital Giessen, Giessen, Germany. Background: Human papillomavirus (HPV) is an independent risk factor for the development of up to 50% of oropharyngeal squamous cell carcinomas (OSCC). They are mainly associated with HPV16. HPV-positive tumors show typical histopathological and molecular features, and patients show less alcohol and tobacco intake and a more favorable survival than the HPV-negative entity of tumors. Controversy exists on the physical status of the virus in OSCC and on HPV integration being an essential factor for tumor development. Whereas in cervical intraepithelial neoplasia lesions oncogenic HPV integrates into the cellular genome upon transition to carcinoma, for HPV-related OSCC this is unclear. Design: Our research group has collected a series of 66 HPV-positive OSCC and 6 cell lines. The physical status of these samples was analysed with a set of independent techniques to detect viral integration, including APOT-and DIPS-PCR to detect virushuman fusion sites, the new MLPA-PCR technology to quantify viral load and ratios between HPV oncogenes E6/E7 and E2, and FISH. Results: HPV16 integration in the cellular genome was identifi ed in 42% of OSCC. HPV integration sites were distributed all over the genome and were preferably found in gene loci, often with reported involvement in tumorigenesis, including BCL2, FANCC, TRAF3 and TP63. In these cases both integration in exon and intron sequences was detected. In addition, half of the integration sites are in close proximity to fragile sites.
Conclusions:
In conclusion, this is the fi rst study providing evidence for and a detailed analysis of HPV 16 integration sites in approximately half of HPV-positive OSCC. We were unable to identify viral integration in the remaining tumours by means of APOT and DIPS PCR, indicating that these tumours harbor episomal HPV copies and/or integration of complete episomes. Studies are ongoing to further examine HPV-driven tumorigenesis in both subgroups.
Association between Stromal Myofibroblasts and Molecular, Clinical, and Histopathological Features of Premalignant and Malignant
Lip Lesions ML Spencer, P Zapata, A Martinez, N Riquelme, O Salvatori, IG Rojas. College of Dentistry, University of Concepcion, Concepcion, Chile. Background: Tumor stroma composition is an important prognostic factor in several neoplasias. An increased density of stromal myofi broblasts is associated with higher tumor aggressiveness and mortality in oral squamous cell carcinoma (SCC). Lip SCC is a type of oral cancer characterized by altered p53 and COX-2 expression as well as by an activated stroma both in its premalignant and malignant stages, and includes increased angiogenesis, infl ammatory infi ltration and fi broblast density. Since myofi broblasts have not been characterized during lip carcinogenesis, the aim of this study was to assess myofi broblast density and its association with molecular and clinicopathological features of both the premalignant lip lesion, actinic cheilitis (AC) and lip SCC. Design: Sixty two AC samples (11 with dysplasia) and 54 lip SCC samples were processed for immunohistochemical detection of myofi broblasts with the marker smooth muscle actin (SMA). Immunohistochemical detection of p53 and COX-2 was also performed. Samples were scored 1 if SMA+ cells corresponded only to blood vessels, 2 if SMA+ myofi broblasts were <50% of the stroma, and 3 if SMA+ myofi broblasts were >50% of the stroma. Scores (based on intensity and extension) were also obtained for p53 and COX-2 expression at the epithelial or tumor compartments of each sample. Results: Myofi broblasts were signifi cantly increased in lip SCC (55%) as compared to AC (13%) (P<0.0001, Fisher´s Exact test). In lip SCC samples, 44% had score 1, 24% score 2, and 31% score 3. In AC samples, 86% had score 1 and 13% score 2, with no score 3. Female patients with lip SCC showed higher stromal myofi broblast density than males (P<0.05). Myofi broblast density had no association with TNM stage or tumor differentiation, however, it was associated with epithelial dysplasia in AC (P<0.05). Stromal myofi broblast density was also associated with p53 expression both in AC and lip SCC (P<0.0001, t-test), but no association was found with COX-2 expression. Conclusions: Myofi broblast density increases as lip cancer progresses, and it is associated with gender (higher in females) and p53 expression. This suggests that stromal myofi broblasts are important markers of malignancy during lip carcinogenesis. Supported by CONICYT Chile, grant FONDECYT 1090287. Background: Dedifferentiated acinic cell carcinoma (ACC) is a rare variant composed of low-grade (LG) ACC and a high-grade (HG) dedifferentiated component, either poorly differentiated adenocarcinoma or undifferentiated carcinoma. Given its aggressive clinical course, dedifferentiated ACC is important for surgical pathologists to recognize. Since only twenty cases have been reported and characterized to date, our goal was to describe the clinical, morphologic and immunophenotypic spectrum of six new cases. Design: An institutional review from 1990-2011 for dedifferentiated ACC and highgrade carcinoma, not otherwise specifi ed (NOS) identifi ed six total cases. Clinical information and tissue were available for six and fi ve cases, respectively. We evaluated the histologic features as well as immunophenotype using antibodies to CAM5.2, actin (SMA), S100, p63, p53, Ki-67, cyclinD1, β-catenin, estrogen receptor (ER), Her-2/neu, and androgen receptor (AR). Five LG ACC were stained for comparison. Results: Median age was 55.5 y (range 47-70 y), with equal sex predilection and all occurred in the parotid. Half involved the facial nerve at presentation. Most (5/6) patients received total parotidectomy and LN dissection with adjuvant therapy (4/6). Distant metastasis occurred in 3/5 and LN metastasis in 4/5 cases over a median of 12.5 m (range 9-24 m). 4/5 died with a median survival of 2.8 y (range 0.9 -8.8 y) and one is alive with disease. All were composed of LG microcystic ACC and a HG component consisting of invasive lobules of undifferentiated cells. Cribriform growth was seen in 2/5 and glands in 3/5. All HG areas had cells with acinic differentiation and these were prominent in 4/5. Perineural invasion, high mitotic rate, atypical mitoses and comedonecrosis were each seen in 4/5 cases. Compared to the LG ACC, the dedifferentiated components showed decreased S100 dendritic cells and CAM5.2 staining with increased cyclinD1, p53 and Ki-67. All cases were positive for membranous β-catenin and all were negative for p63, S100, SMA, AR, ER and Her-2/neu. Conclusions: Dedifferentiated ACC demonstrated an aggressive clinical course with frequent facial nerve involvement, metastases and death. No definitive immunophenotypic profi le could be determined from this small cohort, but the increased cyclinD1, p53 and Ki-67 are consistent with a more aggressive neoplasm. Although some may resemble salivary duct carcinoma, the negative AR and Her-2/neu argue against this. Recognition of dedifferentiated ACC is important for surgical pathologists as more aggressive clinical management is warranted. (HNSCC) . The aims of this study were twofold: fi rst, to determine if FFPE is an acceptable sample type for the multiplex miRNA expression assays, and, second, to identify miRNA expression patterns that may be characteristic of HNSCC when compared to matched normal tissues. Design: Total RNA was extracted and purifi ed from 24 archived FFPE matched tumor and normal HNSCC (6 laryngeal, 6 oral tongue) using the Qiagen RNeasy FFPE kit. Approximately 100ng of total RNA was run in a fi nal reaction volume of 30ul using nanoString's nCounter miRNA Expression Assay Kit on the nCounter platform. This assay detects over 700 miRNAs in a multiplex format. The geometric mean of the top 150 expressing miRNAs was taken for normalization. The expression of miRNAs in tumor tissues was compared to the matched normal counterparts. Results: Two of 24 samples (1 tumor, 1 normal) showed low counts, indicating possible degradation, therefore, a total of 10 sample pairs had analyzable results (4 laryngeal and 6 tongue). The tumors expressed a median of 147 miRNAs (range 82-435) and the normal tissues expressed a median of 133 miRNAs (range 107-224). Several patterns of expression were observed: miR-21 was upregulated in 7/10 cases (3-14 fold) including 5/6 tongue tumors. MiR-205 and miR-1274b were upregulated in 5/10 total cases (3-10 fold) and in 4/6 tongue tumors (3-4 fold), respectively. MiR-451and miR-125b showed downregulation in 6/10 (3-72 fold) and 5/10 (3-12 fold) total tumors, respectively. Conclusions: In this study, we have shown that the nCounter miRNA Expression Assay Kit can be successfully run on HNSCC FFPE archival tissue. Our fi ndings of the upregulation of miR-21 in HNSCC are consistent with prior reports in the literature. In addition, we identifi ed other miRNAs that may play a regulatory role in the tumorogenesis of HNSCC and that may have a tumor site specifi c profi le (i.e. tongue vs. larynx) that lend themselves to further investigation. This study evaluates p53 expression in HPV positive and HPV negative OSCC patients with and without smoking history. Design: 101 cases of OSCC, 65 p16 positive and 36 p16 negative patients were retrospectively collected. The two groups have been divided in nonsmokers, smokers and patients with remote smoking history (who quit smoking at least 3 years prior to diagnosis). Immunohistochemistry stains for p16 and p53 were performed on all cases. The staining pattern for p53 has been defi ned as low expression (less than 20% of the nuclei positive) or high expression (more than 20% nuclear staining). Results: There were signifi cant differences in p53 staining pattern between p16 positive and p16 negative patients. P16 negative smokers (current and remote smokers) had the highest percentage of p53 overexpression (38 and 40%, respectively). The highest percentage of p53 overexpression in the p16 positive patients was in the smokers group, 15% of cases. In p16 positive nonsmokers only 4% of patients showed high p53 staining. p53 levels in nonsmokers, p16 positive and p16 negative was low (under 10%). Conclusions: In the p16 negative group, patients with current and remote smoking history showed the highest p53 expression. This is concordant with the literature data that suggests that p53 is overexpressed in non HPV related head and neck SCC. Our study brings strong evidence that in HPV positive patients with OSCC that are current smokers there is an increase in p53 expression, at a level that is intermediary between p16 positive nonsmokers and p16 negative smokers. We hypothesize that smoking partially reverses the effect of E6 HPV protein on p53 inactivation. The small percentage of HPV positive nonsmokers with high p53 expression suggests that in HPV OSCC other pathways, independent of HPV, may be involved in p53 inactivation, hypothesis that may carry therapeutic and prognostic implications. However, in many patients with OSCC, HPV is not the only carcinogen and superimposed chemical/toxin carcinogens (smoking and alcohol) often play an important role in tumor initiation and progression. The objective of this study is to explore the p16/Rb pathway in patients with p16 positive and p16 negative OSCC. Design: Rb and p16 expression was evaluated by immunohistochemistry in 66 cases of p16 positive and 36 cases of p16 negative OSCC. Smoking history was available in all cases. Rb expression was assessed as low if 20% or less of tumor cells showed nuclear staining and high if nuclear staining was present in more than 20% of tumor cells. p16 was considered positive if more than 50% of the tumor cells demonstrated cytoplasmic and nuclear staining. Results: More than 50% of the 66 patients with p16 positive OSCC showed low Rb (59% in nonsmokers, 73% in remote smokers and 62% in smokers). The remaining p16 positive patients had high Rb expression. Among the 36 cases of p16 negative OSCC, 100% of smokers had high Rb expression, while in the nonsmoker and remote smoker groups only 20% of patients showed high Rb expression. Conclusions: Low Rb expression in p16 positive OSCC is in agreement with the effect of HPV E7 oncoprotein on the p16/Rb axis. However, approximately 30% of p16 positive patients had high Rb expression, irrespective of their smoking history. This may be due to differences in the degree of Rb inhibition by E7 oncoprotein, making the HPV action on the host cell more important than patients' smoking history. High Rb expression in p16 negative OSCC supports the hypothesis that cell proliferation in HPV negative tumors may involve loss or silencing of the p16 tumor suppressor via a pathway independent of Rb activity.
P53 Expression in Oropharyngeal Squamous
B7-H1 Expression Model for Immune Evasion in Human
Papillomavirus Associated Squamous Cell Carcinomas OC Ukpo, WL Thorstad, JS Lewis. Washington University, Saint Louis, MO. Background: Human papillomavirus (HPV) has been associated with oropharyngeal squamous cell carcinomas (OSCC). Persistent viral infection is postulated as the mechanism leading to carcinogenesis. It is known that immune evasive cells can provide an ideal niche for a virus. The B7-H1/PD-1 cosignaling pathway plays an important role in viral immune evasion by making CD8+ cytotoxic T-cells anergic. Tumor cell B7-H1 expression has also been associated with poorer survival in numerous carcinomas, but its role in HPV-related OSCCs is unknown. We hypothesized that HPV-related OSCCs express B7-H1 as a potential mechanism for HPV immune evasion. Design: A tissue microarray of OSCC was utilized, for which HPV E6/E7 mRNA by in situ hybridization was previously performed. Immunohistochemistry was performed to detect B7-H1 on tumor cells, which was scored as positive or negative. Either membranous or cytoplasmic staining was considered positive. Screening was performed by two pathologists (OCU, JSL), both blinded to clinical information. Results: B7-H1 was expressed in 82 of the 181 (45.8%) cases. Tumors expressing B7-H1 were more likely to be HPV positive. B7-H1 showed a signifi cant trend toward correlation with distant metastasis in the entire cohort (OR= 2.85, p=0.12), a strong trend in HPV negative cases (OR=7.01, p=0.10), but no trend in the HPV positive cases (OR= 1.56, p=0.63). B7-H1 expression was not associated with recurrence in the entire cohort (OR= 1.09, p=0.80), HPV positive (OR= 0.80, p=0.69) or HPV negative (OR=2.02, p=0.22) cases. B7-H1 was not associated with overall survival for the entire cohort (RR= 0.91, p=0.73) , and HPV positive cases (OR=0.84, p=0.64), but showed a trend toward poorer survival in HPV negative cases (OR= 1.65, p=0.38) . Conclusions: B7-H1 is expressed in a signifi cant subset of tumors with HPV mRNA viral transcript expression. This suggests that B7-H1 positive tumor cells may play a role in harboring persistent HPV infection. However, it does not appear to be associated with tumor recurrence or poorer survival, perhaps due to risk modifi cation by the presence of HPV. Distal metastasis may be associated with B7-H1 expression, but a larger sample size is required. P Vielh, C Richon, G Meurice, B Job, L Lacroix, V Marthy, N Motte, A Valent, B Caillou, A Al Ghuzlan, J-M Bidart, A El Naggar, V Lazar, P Dessen, M Schlumberger. Institut Gustave Roussy, Villejuif, France; MD Anderson Cancer Center, Houston. Background: Although fi ne needle aspiration cytology (FNAC) is an effi cient method for diagnosing the benign or malignant nature of thyroid nodules, distinction between follicular adenomas and carcinomas may still represent a diffi cult task. Identifi cation of distinct genomic alterations between these two groups of tumors, potentially applicable to cytological specimens, should be therefore of major interest. Design: A series of 61 cases consisting of 31 cases of follicular adenomas and of 30 cases of follicular carcinomas were characterized by molecular methods: mutations in the RAS (H, K and N) , BRAF, CTNNB1 and PIK3CA genes were assessed by sequencing, PAX8/PPARg and RET/PTC1 translocations by RT-PCR, and microRNA (miRNA) expression using 8x15K microarrays. Results: Out of the 61 patients, 35 were female and 26 were male with a median age of 59 (21 to 86) and 58 (28 to 83) years, respectively. Median size of follicular adenomas was 3 (1 to 5.5) cm and histological subtypes were microfollicular in 6 (19%) cases, macrofollicular in 9 (29%) cases and of mixed subtype in 16 (52%) cases. Mean size of follicular carcinomas was 3.7 (1 to 15) cm and subtypes were microinvasive in 18 (60%) cases and widely invasive in 12 (40%) cases. Mutations (n=1) and translocations (n=0) were rarely found in adenomas as compared with follicular carcinomas (n=11 and n=3, respectively). After data processing, 281 miRNA were validated for further analysis. An unsupervised clustering of 57 tumor samples (adenomas and carcinomas) shows two well distinct clusters: the fi rst one covers 26 out of 28 carcinomas (93%) whereas the second one covers 28 out of 29 adenomas (97%). The differential analysis of carcinomas versus adenomas raised 20 miRNA: 19 were over-expressed in carcinomas, and one in adenoma. Further analysis of these 20 miRNA allows us to identify a signature composed of 10 miRNAsdistinguishing adenomas from carcinomas. Conclusions: In conclusion, follicular lesions of the thyroid are clearly differentiated by the study of a small subset of miRNAs. Further studies are needed to verify these data before being used as an adjunct for helping the differential diagnosis between follicular adenomas and follicular carcinoma on cytological material obtained by FNAC, and to explore their functional signifi cance.
Molecular Characterization of 61 Cases of Follicular Adenomas and Carcinomas of the Thyroid
A Cost-Effectiveness Analysis of Thyroid Frozen Sections
SM Voss, HS Crist, H Mani. PSMSHMC, Hershey, PA. Background: Routine use of frozen sections (FS) during thyroid surgery continues to be controversial. Studies have advocated the use of FS only in cases labeled suspicious or indeterminate on cytology (FNAC). We performed a cost-effectiveness analysis of thyroid FS use to evaluate the above strategy. Design: A retrospective analysis of the pathology database was performed to identify thyroid FS over a 7-year period. Results of FNAC, FS and fi nal pathology (FHP) were collated and data analyzed. Cost effectiveness was analyzed based on medicare reimbursement rates for FNAC ($134), FS ($89), surgery (lobectomy $767, thyroidectomy $970) and FHP ($219). Results: 152 thyroid FS were carried out in the study period. FS diagnoses correlated with FHP in 128 (84%) cases (33 malignant and 95 benign). FS had a sensitivity of 64% and specifi city of 94%. 115 cases had satisfactory FNAC, with a sensitivity of 73% and specifi city of 64%. Of the 33 cases diagnosed as malignant on FS, 17 had a diagnosis of malignancy on FNAC and FS did not add to the surgical strategy in these cases. FS changed the surgical strategy in 20 (13%) cases that were not malignant by FNAC. Diagnoses on FS and FHP in non-malignant FNAC categories are shown in Table 1 . False negative diagnoses on FS included 11 papillary carcinomas (8 micro and 3 follicular variant) and 3 minimally invasive follicular carcinoma. Based on our data, if FS had been performed in all the 125 cases that did not have a preoperative FNAC diagnosis of malignancy, and if surgical strategy of lobectomy vs. total thyroidectomy had been based on FS diagnosis in these cases, the total cost would be $85628. On the other hand, if FS were performed only in the 15 cases with a diagnosis of suspicious/indeterminate on FNAC, there would be a saving of $9790 on FS costs. However, this strategy would have missed the 6 malignancies that were diagnosed on FS in other FNAC categories (Table 1) . These 6 would have required completion lobectomy at a second sitting (cost $5916), reducing the savings to $3714. It is likely that other costs of second hospitalization and lost man-hours at work would outweigh these limited savings. Conclusions: Intraoperative FS does not yield additional information in cases with an FNAC diagnosis of malignancy. FS is both cost-effective and impacts surgical strategies in cases with non-malignant FNAC diagnoses. Background: Spindle cell carcinoma (SpCC) is a rare variant of squamous cell carcinoma characterized by spindled or pleomorphic cells which appear to be a true sarcoma but are actually of epithelial origin. Recent studies have shown that certain variants of head and neck squamous cell carcinoma are human papillomavirus (HPV) -related and are associated with more favorable outcomes. The purpose of this study was to determine the prevalence of HPV in SpCC and to explore the effect of HPV status on patient outcomes. Design: Cases with a diagnosis of SpCC, sarcomatoid carcinoma, or SCC with a spindle cell component were retrieved from pathology department files. The diagnosis required a biphasic lesion with a clearly recognizable squamous neoplastic component or alternatively a pure spindle cell or pleomorphic tumor with documented immunohistochemical positivity for epithelial cell markers. The presence of transcriptionally-active HPV was determined by p16 immunohistochemistry and both DNA and RNA in situ hybridization (ISH) for high risk HPV E6 and E7 transcripts. We also reviewed the medical records and follow up information for all patients. Results: Of 32 cases, 5 (15.6%) were from the oropharynx, 12 (37.5%) from the oral cavity, 1 (3.1%) from the maxillary sinus, and 14 (43.8%) from the larynx or hypopharynx. The average stage at presentation of patients with oropharyngeal SpCC was higher when compared to other sites but there were too few patients to determine statistical signifi cance. None of the oropharyngeal SpCCs were positive for p16 or for high risk HPV by DNA or RNA ISH. Only one of the 27 non-oropharyngeal SpCC (oral cavity) was HPV positive by both DNA and RNA ISH. It also stained for p16. Another SpCC from the larynx was HPV positive by both DNA and RNA ISH in both components, but it did not stain for p16. A third case from the maxillary sinus was positive for p16 in the conventional SCC component but negative for HPV by ISH. Both HPV positive patients presented at high stage (IV), and they died with disease at 22 and 9 months after diagnosis, respectively. Conclusions: The majority of SpCCs of the head and neck, including the oropharynx, are not HPV related, and for the rare HPV-related cases, the presence of HPV does not appear to provide any prognostic benefi t, although the number of cases is insuffi cient to make any defi nitive conclusions. Background: Adenoid cystic carcinomas (AdCCs) are malignant tumours that affect multiple anatomical sites, including the salivary gland, lung and breast. 30%-90% of these tumours harbour the MYB-NFIB fusion gene, caused by a t(6:9) translocation, which results in MYB overexpression. Salivary gland and breast AdCCs have distinct clinical behaviours; while salivary gland AdCCs are prone to distant relapses, patients with breast AdCCs have an excellent prognosis. The aim of this study was to investigate the presence of mutations in known oncogenes in AdCCs. Design: Twelve MYB-NFIB-positive and one MYB-NFIB-negative breast AdCCs were microdissected to ensure >90% of tumour cell content, and DNA was extracted. The prevalence of hot-spot mutations in 19 known oncogenes was assessed using the Sequenom OncoCarta Panel v1.0, and validated with Sanger sequencing. Genes identifi ed as mutated in any of the cases, and genes related to the same canonical pathways as those of the mutated genes, were sequenced in a separate cohort of 56 AdCCs (2 breast, 4 lung, 48 salivary gland, 1 pancreatic and 1 vaginal wall) using Sanger sequencing. Results: Using Sequenom MassArray we identifi ed BRAF mutations (i.e. V600E and G464E) in 2/13 breast AdCCs (15%), which were confi rmed by Sanger sequencing. Both cases harbouring BRAF mutations were MYB-NFIB fusion-positive. No hotspot mutations in BRAF and other genes of the RAS-RAF pathway, namely NRAS, KRAS and HRAS, and also in KIT, a gene previously reported to be mutated in AdCCs, were identifi ed in a separate cohort of 56 AdCCs by Sanger sequencing. Conclusions: A subset of breast AdCCs, but not AdCCs from other anatomical sites, harbour activating BRAF mutations, albeit of low prevalence. These data provide evidence to suggest that the RAS-RAF pathway may be activated in tumours of indolent clinical outcome, such as breast AdCCs. Additional studies testing whether BRAF mutations constitute a 'driver' event in MYB-NFIB-positive AdCCs are warranted. Mutations in the genes assessed by Oncocarta v1.0 are unlikely to account for the differences in clinical behaviour between AdCCs of different anatomical sites. Finally, the lack of KIT mutations in our cohort suggests that KIT overexpression is unlikely to constitute a useful therapeutic target for AdCCs.
